Endo International plc, a global specialty pharmaceutical company, announced the appointment of Joseph J Ciaffoni as president, US branded pharmaceuticals, effective August 15, 2016.  

"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our US branded business," said Rajiv De Silva, president and CEO of Endo. "I look forward to Joe's leadership and contributions to our branded organization and working with him to effectively deliver Endo's innovative therapies to patients with significant unmet need."

"Additionally, I would like to extend my sincere thanks to Brian Lortie for his continued leadership in this role during the transition. We wish Brian much continued success in his future endeavours," added De Silva.

Prior to joining Endo, Ciaffoni served as senior vice president, Global Specialty Medicines Group for Biogen. In this role, he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Ciaffoni started his employment with Biogen Idec in 2012 and during his tenure held senior roles including senior vice president, US commercial and vice president, US neurology field operations and marketing. Prior to joining Biogen, Ciaffoni was executive vice president and chief operating officer of Shionogi Inc. and president of Shionogi Pharmaceuticals. Previously, he served as vice president, sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Ciaffoni holds a B.A. in Communications and an M.B.A. from Rutgers, The State University of New Jersey.

"I am thrilled to be joining Endo at a time of such significant opportunity for the business," said Ciaffoni. "I look forward to leading Endo's US branded pharmaceutical business, driving the development and execution of Endo's branded strategy and accelerating key growth drivers while, ultimately, helping improve patients' lives."